Clinical Trials for Depression

Depression is a complex illness with multiple factors that contribute to its development, such as genetic, environmental, and social factors. While some individuals may find relief from depression through therapy or medication, others may require additional treatment options.

Clinical trials for depression treatments offer hope for individuals who have not found relief from conventional treatment methods. These research studies are an opportunity to test new and innovative treatments for depression. In this article, we will explore clinical trials for depression, the current status of depression research, and different criteria for participating in depression clinical trials.

What Are Clinical Trials for Depression?

Clinical trials for depression are studies that involve testing new treatments or medications to help people with depression. These studies are conducted by medical researchers, and the purpose of the studies is to evaluate the effectiveness and safety of the new treatment or medication on depression symptoms.

Current State of Depression Treatment Research

Currently, there are many clinical trials underway (more than 2,000 ongoing clinical trials) to test new treatments for depression.3 Some of these trials are focused on developing new medications that work in different ways than existing antidepressants. Some other clinical trials are testing non-medication treatments for depression, such as talk therapy or light therapy.

Researchers are also exploring new technologies, such as brain stimulation, to treat depression.4

One promising area of research involves using psychedelic drugs, such as psilocybin (substance in so-called “magic mushrooms”) and MDMA (commonly known as ecstasy), to treat depression. These drugs have shown potential in clinical trials for treating depression and other mental health conditions.5,6 Exciting research has shown that a single dose of psilocybin can have long-lasting benefits for cancer patients dealing with anxiety and depression.7

Researchers are currently investigating a new medication called ezogabine as a potential treatment for major depressive disorder (MDD). Ezogabine belongs to a class of drugs known as potassium channel openers. These medications work by affecting the activity of certain channels in the brain, which can have an impact on mood and brain function.8

Furthermore, researchers have shown that high doses of a non-invasive brain stimulation technique known as magnetic brain stimulation can significantly benefit individuals with severe depression. This technique, called transcranial magnetic stimulation (TMS), involves using magnetic fields to stimulate specific regions of the brain. In recent clinical trials, researchers tested a new approach to TMS treatment for severe depression. The results were highly promising. In the trial, an impressive 79 percent of participants with severe depression achieved remission from their depressive symptoms. Remission refers to a state where the symptoms of depression are significantly reduced or completely resolved.9

In addition to developing new treatments, clinical trials also aim to improve the delivery and accessibility of existing treatments. For example, some trials are testing telehealth platforms that allow people to receive treatment for depression from the comfort of their homes.7

Telehealth platforms use technology to provide healthcare services remotely, including mental health treatment for depression. Instead of going to a therapist’s office, individuals can receive therapy or consultations from the comfort of their own homes through videoconferencing or other digital communication methods.

Researchers want to understand if therapy delivered through telehealth is as effective as traditional in-person therapy and whether it can provide comparable outcomes. They also assess factors like patient satisfaction, convenience, and the impact of telehealth on treatment results.10

Overall, there is a lot of exciting research happening in the field of depression treatment. While there is still much to be learned about the causes and treatment of depression, these developments offer hope for those suffering from this debilitating condition.

Criteria for Current Depression Clinical Trials

Find Clinical Trials Near Me

Interested in clinical trials? Simply search by postal code and type of condition to see what’s going on in your area.

US
AU
CA
IE
ZA
GB
US

Each clinical trial has certain criteria that participants must meet to be eligible to participate. Here are some common criteria for participants of clinical trials for depression:

Age: Many clinical trials have age requirements. For example, some trials may be open only to adults over the age of 18, while others may be open only to adolescents or children.

Diagnosis: Participants in depression trials must have a diagnosis of Major Depressive Disorder. The specific type of depression may vary depending on the trial.

Severity: The severity of depression may also be a factor in determining eligibility for a trial. Some trials may be open only to people with severe depression, while others may include people with milder forms of the condition.

Medication History: Some trials may require participants to have previously tried and failed to respond to traditional antidepressant medications.

Health History: Participants in depression trials must meet certain health criteria. For example, they may need to have certain lab tests or physical exams to ensure they are healthy enough to participate.

Other Treatments: Some trials may require participants to refrain from other forms of depression treatment, such as talk therapy or other medications, during the trial period.

While there is still much to be learned about the causes and treatment of depression, clinical trials offer hope for those suffering from this debilitating condition. By participating in these trials, individuals with depression can contribute to the development of new and better treatments and potentially improve their symptoms and quality of life.

Last updated: 11/06/2023Last medically reviewed: 06/26/2023

Medical Disclaimer: The information provided in this article is not a substitute for the advice of qualified healthcare professionals. While we strive to publish accurate information, it is not possible to cover all potential scenarios, including drug or treatment effects, interactions, or usage. You should not rely solely on this article to determine whether a particular treatment, drug, or clinical trial is suitable for you or any other individual. Always consult a healthcare professional before starting or changing any treatments.

Sources

  1. Transforming Clinical Research in the United States: Challenges and Opportunities: Workshop Summary. Clinical trials in depression. Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Washington (DC): National Academies Press (US); 2010.
  2. Clinical Trials: What You Need To Know. Types and Phases of Clinical Trials. Accessed from: https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html
  3. US National Library of Medicine. Accessed from: https://www.cancer.org/treatment/treatments-and-side-effects/clinical-trials/what-you-need-to-know/phases-of-clinical-trials.html
  4. Wu Y et al. Deep brain stimulation in treatment-resistant depression: A systematic review and meta-analysis on efficacy and safety. Front Neurosci. 2021 April 01;15:655412.
  5. Kvam TM et al. Study protocol for "MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study". Front Psychiatry. 2022 Oct 26;13:954388.
  6. Davis AK et al. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. 2021 May 1;78(5):481-489.
  7. Griffiths RR et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016 Dec;30(12):1181-1197.
  8. Costi S et al. Impact of the KCNQ2/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: Results from a randomized controlled trial. Am J Psychiatry. 2021 May 1;178(5):437-446
  9. Erickson M. Experimental depression treatment is nearly 80% effective in controlled study. Accessed from: https://med.stanford.edu/news/all-news/2021/10/depression-treatment.html
  10. Choi NG et al. Effect of telehealth treatment by lay counselors vs by clinicians on depressive symptoms among older adults who are homebound: A randomized clinical trial. JAMA Netw Open. 2020 Aug 3;3(8):e2015648.
  11. Palylyk-Colwell E, Argáez C. Telehealth for the assessment and treatment of depression, post-traumatic stress disorder, and anxiety: Clinical evidence. Accessed from: https://www.ncbi.nlm.nih.gov/books/NBK532701/
  12. ClinicalTrials.gov. Clinical trial database. Accessed from: https://clinicaltrials.gov/ct2/home
  13. Clinical trial database. Accessed from: https://www.centerwatch.com/clinical-trials/listings/
  14. Clinical trial database. Accessed from: https://www.researchmatch.org/